Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate

Brachytherapy

Volumn 11, Issue 4, 2012, Pages 292-298

  Myers, Michael A ^a   Hagan, Michael P ^a   Todor, Dorin ^a   Gilbert, Lynn ^a   Mukhopadhyay, Nitai ^a   Randolf, Jessica ^a   Heimiller, Jeffrey ^a   Anscher, Mitchell S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hypofractionated; IMRT; Prostate cancer; Single fraction HDR boost

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; BICALUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; STEROID;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DYSURIA; FECES INCONTINENCE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; IMPLANT; INTENSITY MODULATED RADIATION THERAPY; MALE; NOCTURIA; PATIENT SAFETY; PELVIS LYMPH NODE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSTATE; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM HEMORRHAGE; SIGMOIDOSCOPY; URETHRA STRICTURE; URINARY FREQUENCY; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84862558532     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.07.006     Document Type: Article

References (31)

1. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
2. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
3. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.
4. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176:1415-1419.
5. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
6. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:316-327.
7. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
8. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007, 84:114-120.
9. Martinez A., Gonzalez J., Stromberg J., et al. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995, 33:1019-1027.
10. Pieters B.R., van de Kamer J.B., van Herten Y.R., et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008, 88:46-52.
11. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
12. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:24-33.
13. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
14. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66:1072-1083.
15. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
16. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
17. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048-1055.
18. Kalkner K.M., Wahlgren T., Ryberg M., et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol 2007, 46:909-917.
19. Cury F.L., Duclos M., Aprikian A., et al. Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy. Brachytherapy 2010, 9:208-212.
20. Morton G.C., Loblaw D.A., Sankreacha R., et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010, 77:811-817.
21. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150.
22. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999, 45:59-67.
23. Duchesne G.M., Williams S.G., Das R., et al. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results. Radiother Oncol 2007, 84:128-134.
24. Sato M., Mori T., Shirai S., et al. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:1002-1009.
25. Morton G.C. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005, 17:219-227.
26. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533.
27. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004, 60:1013-1015.
28. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
29. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92:488-498.
30. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
31. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.